E
Evonetix
Ur desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not…
About Evonetix
Evonetix is a pioneering biotech company based in Cambridge, focused on revolutionizing the field of synthetic biology through its innovative DNA synthesis platform. The company serves researchers and institutions in the biotechnology and life sciences sectors, providing them with a highly parallel desktop platform that enables the synthesis of DNA with unprecedented accuracy, scale, and speed. Operating in the rapidly growing synthetic biology market, Evonetix's business model revolves around the commercialization of its proprietary technology, which facilitates the creation and manipulation of genetic material. This platform democratizes access to DNA synthesis, allowing researchers to conduct experiments and develop applications more efficiently and cost-effectively. Evonetix generates revenue through the sale of its DNA synthesis platform and related services, targeting a broad range of clients from academic institutions to commercial biotech firms. The company's innovative approach has earned it recognition, including being named Biotech Scale up of the Year at the 2020 Business Weekly Awards. Keywords: DNA synthesis, synthetic biology, biotech, desktop platform, gene synthesis, biotechnology, life sciences, innovation, Cambridge, research tools.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Cambridge, United Kingdom
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 69.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Synthetic Biology, Genome Engineering, Sustainable Development Goals, Biotech and Pharma, BIA Techbio UK
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2023 | $24M | $149M | Providence Investment Company · Foresite Capital · Molten Ventures · Cambridge Consultants | ↗ |
| SERIES BOther financing | Mar 2020 | $30M | $119M | Molten Ventures · Collective Data · Foresite Capital | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Evonetix is 310 monthly website visits, down 74.2% over the last three months. Evonetix's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Molten Ventures
DCVC
Civilization Ventures
Cambridge Consultants
Foresite Capital
Collective Data- PCProvidence Investment Company
Morningside
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Evonetix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evonetix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.